Statement of Limitations (1/2) The following is a series of presentations (the "Presentation") prepared by Roivant Sciences Ltd. and certain of its subsidiaries and affiliates (the "Company"). This Presentation is only f

Roivant R&D Day September 28, 2021

Statement of Limitations (1/2) The

following is a series of presentations (the "Presentation") prepared by Roivant Sciences Ltd. and certain of its subsidiaries and affiliates (the "Company"). This Presentation is only for its intended investor audience, and

for informational purposes only, and it is not intended for reproduction or any further dissemination without the Company's consent. This Presentation does not constitute an offer to sell or solicitation of an offer to buy securities of any

nature whatsoever, in any jurisdiction, and it may not be relied upon in connection with the purchase of securities. This Presentation It is not intended to form the basis of any investment decision or any other decisions with respect of the

proposed transactions (the "Business Combination") contemplated by the Business Combination Agreement, by and among Montes Archimedes Acquisition Corp. (the "SPAC"), and the Company and should not be relied upon in connection

with any investment decision. The information contained herein does not purport to be all-inclusive and none of the SPAC, the Company or any of their respective affiliates, directors or officers makes any representation or warranty, express or

implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. Forward Looking Statements This Presentation may contain forward-looking statements for the purposes of the safe harbor

provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements include, without limitation, statements regarding the estimated future financial performance, financial

position and financial impacts of the Business Combination, the satisfaction of closing conditions to the Business Combination and any related financing, the level of redemption by the SPAC's public stockholders, the timing of the completion

of the Business Combination, anticipated ownership percentages of the combined company's stockholders following the potential transaction, and the business strategy, plans and objectives of management for future operations, including as they

relate to the potential Business Combination. Future results are not possible to predict. Opinions and estimates offered in this Presentation constitute the Company's judgment and are subject to change without notice, as are statements about

market trends, which are based on current market conditions. This Presentation contains forward-looking statements, including without limitation, forward-looking statements that represent opinions, expectations, beliefs, intentions, estimates or

strategies regarding the future of the SPAC and the Company and its affiliates, which may not be realized. Forward-looking statements can be identified by the words, including, without limitation, "believe," "anticipate,"

"continue," "estimate," "may," "project," "expect," "plan," "potential," "target," "intend," "seek," "will,"

"would," "could," "should," or the negative or plural of these words, or other similar expressions that are predictions or indicate future events, trends or prospects but the absence of these words does not

necessarily mean that a statement is not forward-looking. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans as they relate to the Business Combination,

are also forward-looking statements. In addition, promising interim results or other preliminary analyses do not in any way ensure that later or final results in a clinical trial or in related or similar clinical trials will replicate those interim

results. The product candidates discussed herein are investigational and not approved and there is no assurance regarding any possible progress in the clinical trials, timing and results of the clinical trials, potential drug profile and points of

differentiation for the potential drug candidates, the safety and efficacy of the potential drug candidates, the timing and commercial success of the product candidates, strategies for completion and likelihood of success for our business and

activities, development plans, target product profiles, regulatory activities, competitive position, market opportunity, potential pricing and reimbursement claims, potential growth opportunities or that any product candidates will ever receive

regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions that are inherently uncertain and that could cause actual results to differ materially from expected results. Many of

these factors are beyond the SPAC's and the Company's ability to control or predict. These risks include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could result in the failure

to consummate the Business Combination; (2) the outcome of any legal proceedings that may be instituted against the SPAC and the Company regarding the Business Combination; (3) the inability to complete the Business Combination due to the failure to

obtain approval of the stockholders of the SPAC or to satisfy other conditions to closing in the definitive agreements with respect to the Business Combination; (4) changes to the proposed structure of the Business Combination that may be required

or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability to meet and maintain Nasdaq's listing standards following the consummation of the

Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of the Company as a result of the announcement and consummation of the Business Combination; (7) costs related to the Business Combination; (8)

changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including risks related to (i) the Company's limited operating history and the

inherent uncertainties and risks involved in biopharmaceutical product development, (ii) the outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes COVID-19, and could adversely impact the Company's business, including its

clinical trials and pre-clinical studies. (iii) the Company's ability to successfully identify new product candidates to develop, acquire or in-license and its drug discovery efforts, which may not be successful, (iv) the regulatory approval

process for new drugs, and ongoing regulatory obligations for approved product candidates, (v) regulatory and legislative developments in the healthcare industry, (vi) the Company's ability to attract and retain key personnel, (vii) the

Company's international operations and (viii) the Company's ability to obtain and maintain intellectual property protection for its technology and product candidates; (10) the risk that we may not be able to raise financing in the

future; (11) the risk that we may not be able to retain or recruit necessary officers, key employees or directors following the Business Combination; (12) the risk that our public securities will be illiquid; (13) the effect of COVID-19 on the

foregoing, including the SPAC's ability to consummate the Business Combination due to the uncertainty resulting from the COVID-19 pandemic; and (14) other risks and uncertainties indicated from time to time in filings made with the SEC,

including those risk factors described under "Risk Factors" of the Form S-4/A filed with the SEC on August 9, 2021, under "Item 1A. - Risk Factors" of the Company's Quarterly Report on Form 10-Q filed with the SEC

on September 21, 2021 and, where applicable, the most recent Annual or Quarterly Reports on Form 10-K or 10-Q, as applicable, filed with the SEC by our SEC registered affiliates, including Arbutus Biopharma Corp., Sio Gene Therapies Inc. and

Immunovant, Inc. Should one or more of these risks or uncertainties materialize, they could cause our actual results to differ materially from the forward-looking statements. We are not undertaking any obligation to update or revise any

forward-looking statements whether as a result of new information, future events or otherwise. You should not take any statement regarding past trends or activities as a representation that the trends or activities will continue in the future.

Accordingly, you should not put undue reliance on these statements in deciding how to make any investment decisions. You are cautioned not to place undue reliance upon any forward-looking statements. Any forward-looking statement speaks only as of

the date on which it was made, based on information available as of the date of this Presentation, and such information may be inaccurate or incomplete. The Company undertakes no obligation to publicly update or revise any such statements, whether

as a result of new information, future events or otherwise, except as required by law.

Statement of Limitations (2/2) Key

Performance Indicators This Presentation may include certain key performance indicators ("KPIs"). Management regularly reviews these and other KPIs to assess the Company's operating results. Realized return on our investments in

Vants and technology sold to Sumitomo Dainippon Pharma Co., Ltd. ("DSP") reflect the value realized directly from the DSP transaction. The Company measures its return on publicly traded Vants by comparing the value of its ownership stake

in the public Vants against its aggregate investment in those entities. The Company believes these KPIs are useful to investors in assessing operating results and returns on historical investments. These KPIs should not be considered in isolation

from, or as an alternative to, financial measures determined in accordance with GAAP. There is no assurance the future investments will achieve similar results Use of Projections This Presentation may contain financial forecasts or

projections with respect to the SPAC, the Company and their respective affiliates. No representation or warranty, express or implied, is made by the SPAC, the Company or their respective affiliates, or the SPAC's or the Company's

or such affiliates' respective directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information contained herein, or any other written, oral or other communications transmitted or otherwise

made available to any party in the course of its evaluation of the Business Combination, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements or otherwise,

relating thereto. Without limiting the generality of the foregoing, no audit or review has been undertaken by an independent third party of the financial assumptions, data, results, calculations and forecasts contained, presented or referred to in

this Presentation. You should conduct your own independent investigation and assessment as to the validity of the information contained in this Presentation and the economic, financial, regulatory, legal, taxation, stamp duty and accounting

implications of that information. This Presentation does not purport to contain all of the information that may be required to evaluate a possible investment decision, and does not constitute investment, tax or legal advice. The recipient also

acknowledges and agrees that the information contained in this Presentation is preliminary in nature and is subject to change, and any such changes may be material. The SPAC and the Company disclaim any duty to update the information contained in

this Presentation. Any and all trademarks and trade names referred to in this Presentation are the property of their respective owners. The SPAC and the Company do not intend the use or display of other companies' trademarks or trade names to

imply a relationship with, or endorsement or sponsorship of the SPAC or the Company by, any other companies. Industry and Market Data In this Presentation, the Company may rely on and refer to certain information and statistics obtained from

third-party sources which they believe to be reliable. The Company has not independently verified the accuracy or completeness of any such third-party information. No representation is made as to the reasonableness of the assumptions made within or

the accuracy or completeness of any such third-party information. Additional Information The Company has filed a proxy statement / prospectus on Form S-4/A with the SEC relating to the proposed Business Combination, which has been mailed to

the SPAC's stockholders. This Presentation does not contain all the information that may be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in

respect of the Business Combination. The SPAC's stockholders and other interested persons are advised to read the proxy statement / prospectus and the amendments thereto and other documents filed in connection with the proposed Business Combination,

as these materials contain important information about the Company, the SPAC and the Business Combination. Stockholders are able to obtain copies of the definitive proxy statement / prospectus and other documents filed with the SEC,

without charge at the SEC's website at www.sec.gov.

Table of Contents Roivant Overview 5

Roivant Discovery 19 Proteovant 35 Genevant 45 Dermavant 61 Immunovant 98 Aruvant 105 Kinevant 123

Roivant: Redefining "Big

Pharma" from End to End Roivant in 2014 Roivant Today Discover Develop Commercialize 1. Create Value 2. Be Contrarian 3. Climb the Wall 4. Sweat the Details 5. Evolve or Die Our Principles 5

How We've Executed on Our Vision

Cited figures and associated investment multiples are Key Performance Indicators. Please refer to the information included on Slide 3 with respect to our KPIs. 1. Medicine, Vant launch, and approval figures include Alliance Vants transferred to

Sumitovant, a wholly-owned subsidiary of Sumitomo Dainippon Pharma ("Sumitomo"), in December 2019. SPIRIT 1 and SPIRIT 2 were completed subsequent to Myovant's transfer to Sumitovant. 2. Based on aggregate Roivant investments in

tech assets and in the five transferred Vants from Vant inception to transaction close, and aggregate proceeds received at closing of the Sumitomo Transaction, excluding (i) a $1BN allocation to Sumitomo's purchase of Roivant equity and (ii)

$99.1M initial liability related to Option Vants. Excludes investment in Sinovant and proceeds received from the termination of Sumitomo's options to purchase Roivant's ownership interests in the Option Vants. 3. The implied enterprise

value of the combined company at the conversion price cap of the new preferred equity investment made concurrently with the merger was $7.0 billion. This enterprise value implies an equity value of $6.1 billion (after netting out approximately $900

million of debt and other adjustments). No assurance can be given that the implied enterprise or equity value is an accurate reflection of the value of the combined business at closing or in the future. At closing of the merger and assuming a $7.0

billion enterprise value, Roivant's ongoing, fully diluted equity ownership in the combined entity was approximately 12% (without giving effect to certain liquidation preferences held by the preferred equity shareholders). Clinical

Achievements 8 positive Phase 3 trials of 9 total1 3 FDA approvals from Vants launched by Roivant and owned by Sumitovant1 >40 medicines brought into development1 NDA for tapinarof accepted for filing; first expected Roivant product launch Small

Molecule Discovery Engine Leading computational drug discovery platform, with proprietary tools for atom-by-atom simulations and a team to continue to push the frontier Broad discovery pipeline of programs designed or optimized in silico to address

challenging, high-value targets Strong Financial Track Record $3BN upfront transaction with Sumitomo Dainippon Pharma (DSP), yielding 4.3x return on Vants and technology sold2 $2BN consolidated cash balance as of June 30 $320M in cash and minority

equity stake in Datavant, following merger with Ciox Health3

8 Consecutive Positive Phase 3 Studies

Note: The FDA has approved relugolix for the treatment of adult patients with advanced prostate cancer and for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The FDA has approved

vibegron for the treatment of adult patients with overactive bladder. Otherwise, the drugs noted above in current pipeline are investigational and subject to health authority approval. Topline results dates are based on corresponding Vant press

releases. Relugolix and vibegron are being developed by Myovant and Urovant, two Vants that were transferred to Sumitovant, a wholly-owned subsidiary of Sumitomo Dainippon Pharma, in December 2019. *SPIRIT 1 and SPIRIT 2 were completed subsequent to

Myovant's transfer to Sumitovant. Trial geography maps indicate continents with trial sites and do not represent all countries within a given continent. Study Drug Indication Patients Enrolled Geography Topline Results Primary p-value PSOARING

1 Tapinarof Psoriasis 510 August 2020 P < 0.0001 PSOARING 2 Tapinarof Psoriasis 515 August 2020 P < 0.0001 SPIRIT 1* Relugolix Endometriosis 638 June 2020 P < 0.0001 SPIRIT 2* Relugolix Endometriosis 623 April

2020 P < 0.0001 HERO Relugolix Prostate Cancer 934 November 2019 P < 0.0001 LIBERTY 2 Relugolix Uterine Fibroids 382 July 2019 P < 0.0001 LIBERTY 1 Relugolix Uterine Fibroids 388 May 2019 P < 0.0001

EMPOWUR Vibegron Overactive Bladder 1,530 March 2019 P < 0.001 MINDSET Intepirdine Alzheimer's Disease 1,315 September 2017 P > 0.05

Gene Therapy Cell Therapy Topical

Biologic Small Molecule Preclinical Phase 1 Phase 2 Phase 3 Registration Note: All drugs in current pipeline are investigational and subject to health authority approval. Development Pipeline Modality TAPINAROF Psoriasis | Dermavant

TAPINAROF Atopic Dermatitis | Dermavant CERDULATINIB Vitiligo | Dermavant IMVT-1401 Myasthenia Gravis | Immunovant IMVT-1401 Warm Autoimmune Hemolytic Anemia | Immunovant IMVT-1401 Thyroid Eye Disease | Immunovant

ARU-1801 Sickle Cell Disease | Aruvant NAMILUMAB Sarcoidosis | Kinevant LSVT-1701 Staph Aureus Bacteremia | Lysovant CERDULATINIB Atopic Dermatitis | Dermavant DMVT-504 Hyperhidrosis | Dermavant

DMVT-503 Acne | Dermavant ARU-2801 Hypophosphatasia | Aruvant AFM32 Solid Tumors | Affivant CVT-TCR-01 Oncologic Malignancies | Cytovant

Leveraged platform expertise to expand

IP with multiple patents expected to provide protection until at least 2036 Hired leadership and provided investment that together delivered Phase 3 success Value Added by Roivant Platform Psoriasis Phase 3: Statistically significant improvement in

PGA score of clear or almost clear with a minimum 2-grade improvement compared to vehicle from baseline (p<0.0001)1 Once-daily, cosmetically elegant, non-steroidal cream that, if approved, could offer a favorable combination of treatment effect,

safety, durability on therapy, and remittive effect Psoriasis and atopic dermatitis affect an estimated 8M and 26M patients in the US, respectively Potential to be used across mild, moderate & severe plaque psoriasis, including sensitive areas

Potential To Transform the Treatment of Psoriasis and Atopic Dermatitis Novel steroid-free topical tapinarof, if approved, could be uniquely positioned to transform two of the largest global immuno-dermatology markets Note: All drugs in current

pipeline are investigational and subject to health authority approval. 1. In both PSOARING 1 and PSOARING 2, adult patients with plaque psoriasis were randomized in a 2:1 ratio to receive once daily (QD) treatment with tapinarof cream, 1% or vehicle

cream. 2. Proportion of subjects who achieved a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from Baseline at Week 12. 3. Proportion of subjects with 75% improvement in Psoriasis

Area and Severity Index (PASI) from Baseline at Week 12. 4. Proportion of subjects with 90% improvement in Psoriasis Area and Severity Index (PASI) from Baseline at any time point. 5. For subjects entering the extension study with a PGA score

of 0, median time to disease worsening (PGA score 2). Mean Treatment Success, % (SEM) Tapinarof 1% QD (n=340) Vehicle QD (n=170) Tapinarof 1% QD (n=343) Vehicle QD (n=172) PSOARING 1 PSOARING 2 25.9% p<0.0001 40.7%

p<0.0001 29.4% p<0.0001 33.9% p<0.0001 Mean Treatment Success, % (SEM) Tapinarof 1% QD (n=340) Vehicle QD (n=170) Tapinarof 1% QD (n=343) Vehicle QD (n=172) PSOARING 1 PSOARING 2 Primary Endpoint: PGA Response2 Key Secondary